

Nadine Kutsch¹, Rudy Ligtvoet¹, Sandra Robrecht¹, Hartmut Linde², Thomas IIImer³, Steffen Doerfel⁴, Joerg Lipke⁵, Ali Aldaoud⁶; Rudolf Schlag⁷, Jolanta Dengler⁸, Othman Al-Sawaf¹, Petra Langerbeins¹, Paula Cramer¹, Barbara Eichhorst¹, Michael Hallek¹, Kirsten Fischer^{1,} Anna Maria Fink¹

¹Department I of Internal Medicine, Center for Integrated Oncology, Aachen Bonn Cologne, Germany; ² Practice for Hematology and Oncology, Dresden; ⁴Onkozentrum Dresden Freiberg; ⁵Practice for Hematology and Oncology, Dortmund; ⁶Practice for Hematology and Oncology, Dresden; ⁴Onkozentrum Dresden Freiberg; ⁵Practice for Hematology and Oncology, Dresden; ⁴Onkozentrum Dresden Freiberg; ⁵Practice for Hematology and Oncology, Dortmund; ⁶Practice for Hematology and Oncology, Dortmund; ⁶Practice for Hematology and Oncology, Dresden; ⁴Onkozentrum Dresden Freiberg; ⁵Practice for Hematology and Oncology, Dortmund; ⁶Practice for Hematology and Oncology, Dresden; ⁴Onkozentrum Dresden Freiberg; ⁵Practice for Hematology and Oncology, Dortmund; ⁶Practice for Hematology and Oncology, Dortmund; ⁶Practice for Hematology and Oncology, Dresden; ⁴Onkozentrum Dresden Freiberg; ⁵Practice for Hematology and Oncology, Dresden; ⁴Onkozentrum Dresden; ⁴Onkozentrum Dresden Freiberg; ⁵Practice for Hematology and Oncology, Dortmund; ⁶Practice for Hematology, Dresden; ⁴Onkozentrum Dresden; ⁴Onkozen Hematology and Oncology, Leipzig; ⁷Practice for Hematology and Oncology, Würzburg; ⁸Practice for Hematology and Oncology, Heilbronn; ⁹Practice for Hematology and Oncology, Aschaffenburg

Bit January City Lay Norman (D) 1 yeak or stated up when the base of two lay of the state of two lay	INTRODUCTION							RESULTS					
curve equations of sources are not accel and produces to be equify. In a feature of the sources are not accel and produces are not accel are not accel and produces are not accel and produces are not acc	BCL2-inhibitors (BCL2i) and BTK-inhibitors (BTKi) have profoundly imp	proved t	he out	come of	⁻ patient	ts (pts)	with						
root root <throot< th=""> root root</throot<>	chronic lymphocytic leukemia (CLL) and are considered standard treatment. However, the translation from							Number of administered prior treatments	Venetoclax			BTKi	
<form>Back Groups Add Link Programmed and order of an art ALL on Freque access of a first of a large of a larg</form>	novel treatments evaluated within clinical trials into routine clinical practice can be complex. The German CLL Number of administered prior treatments								274		915		
	Study Group (GCLLSG) Registry provides real world data of pts with C	CII on ti	herapy	, choices	s outsid	e of clir	nical	Median (Range)		0 (0)-9)	1 (0-1	12)
0 and a control is the resumption of a subject of a resumption	trials in Cormany. We here present data on efficacy and subsequent t	thoronio	norapy		bort of	nte tro		Number of prior treatments, N (%)		274		915	
	with sith an DOL OF () (are stabless) on DTK	liieiapie	5 01 a	large co				= 0 (Venetoclax/BTKi as first-line regimen)		152	(55.5)	352	(38.5)
Methods 19 0 7 12.1 0.2 0.2 0.2 0.2 Any M 2414 and invary MD 2012 are studyed in the mody in 0 0 0.2	with either BCL2i (Venetoclax) or BTKi.							= 1		69	(25.2)	273 157	(29.8)
Add The OCS -1 -1 -1 -2 0								= 3		7	(2.6)	68	(7.4)
	METHODS							= 4		6	(2.2)	37	(4.0)
 Puttern and number of role and we decomposed in particular disconter of a particula								= 5		4	(1.5)	14	(1.5)
Abs -1 <t< td=""><td> Patients with confirmed diagnosis of CLL and with at least one docu </td><td>Imented</td><td>first-lir</td><td>ne CLL t</td><td>treatme</td><td>nt betwo</td><td>een</td><td>= 6</td><td></td><td>2</td><td>(0.7)</td><td>5</td><td>(0.5)</td></t<>	 Patients with confirmed diagnosis of CLL and with at least one docu 	Imented	first-lir	ne CLL t	treatme	nt betwo	een	= 6		2	(0.7)	5	(0.5)
 	July 1 st 2014 and January 30 th 2023 were included in this analysis.							= /		1	(0.4)	5	(0.5)
= 30 0.0 <td< td=""><td>• Treatments were categorized according to the backbone of therapy</td><td>and pts</td><td>were a</td><td>allocated</td><td>d to eith</td><td>er the</td><td></td><td>= 9</td><td></td><td>1</td><td>(0.4)</td><td>0</td><td>(0.0)</td></td<>	• Treatments were categorized according to the backbone of therapy	and pts	were a	allocated	d to eith	er the		= 9		1	(0.4)	0	(0.0)
-11 -11 0 <td>venetoclax or the BTKi cohort depending on their first treatment with</td> <td>n taraete</td> <td>nd anei</td> <td>nts</td> <td></td> <td></td> <td></td> <td>= 10</td> <td></td> <td>0</td> <td>(0.0)</td> <td>2</td> <td>(0.2)</td>	venetoclax or the BTKi cohort depending on their first treatment with	n taraete	nd anei	nts				= 10		0	(0.0)	2	(0.2)
 	venetoelax of the DTN conort depending of their mist treatment with	rarycic	su agei	1113				= 11		0	(0.0)	0	(0.0)
set of the spectra analyzed using Kighun Muser undukant.REALTYINTERMINENT AND	 Treatment sequences were visualized with a sankey-diagram. Time 	e to next	treatm	nent (TT	NT), ev	ent-free)	= 12		0	(0.0)	1	(0.1)
Characterization of 274 glas wave anicous of or 6 wine indication of an intervention of an i	survival (EFS) and overall survival (OS) were analyzed using Kapla	n-Meier	metho	ds.				Last administered prior treatments					
Bit Statistical State S								before first Venetoclax/BTKi regimen		Vene	etoclax	BTKi	
Absist of 2/2 pits were allocated to the BTH pits were allocated to the BTH is cohorts incrit from the first documents that the third documents that here that were allocated to the BTH is cohorts were 20 months (ange 0 - 288) for STM treatment. B <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>All last administered prior treatments</td> <td></td> <td>122</td> <td></td> <td>563</td> <td></td>								All last administered prior treatments		122		563	
• A both Q A ⁺ by Wate all addata be are available about the Wate addata be available about the Wate addata be available addata be av								Chemotherapy		8	(6.6)	45	(8.0)
Network watery water	 A total of 2/4 pts were allocated to the Venetoclax cohort while 915 first therapy using targeted agents 	pts wer	e alloc	ated to	the BTh	Cohor	t as	Chemoimmunotherapy		87	(71.3)	426	(75.7)
mean Construction 1000000000000000000000000000000000000	 Median observation time from the first documented treatment in 	tha Va	notocl	av coho	rt was	26 mor	othe	PI3K-based		14	(11.5)	29	(5.2)
Patient diverse finite and market reliable and the result of a set of a	(range 0 – 296) and 78 months (range 0-266) for BTKi treatment.	the ve	nelocia		IL Was	20 110	1015	Other		13	(10.7)	63	(11.2)
Particle discrete/sites by cohort Venetodax (N = 274) Bits (N = 215) Bits (N = 215) Bits (N = 215) Age (Ventr) 274 295 Discrete/sites (N = 216) 2 (2,1) 1 1 (2,1) 1								Alemtuzumab/Devamethasone		2	(1.6)	/	(1.2)
Pathetic function by contin Number of the pathetic by contin Pathetic function by contin Pathetic function by contin Pathetic function by contin Pathetic by continue by contin by continue by continue by continue by conto								CC-115		0	(0.0)	1	(0.2)
Jack Marketing Jack Marketing <thjack marketing<="" th=""> Jack Marketing Jack M</thjack>	Patient characteristics by cohort	Veneto	clax (N	= 274)	BTKi (N	= 915)		Lenalidomide		2	(1.6)	0	(0.0)
set by: is	Age (years) Median (Bange)	274	71	(32-87)	915	72 (37-97)	Obinutuzumab		2	(1.6)	11	(2.0)
Sender, (vp) 917 913 127 (2.2) 628 628 (6.2) 628 (6.2) (7.2) (7.2	≤ 65 (%)		93	(33.9)		282	(30.8)	Ofatumumab		3	(2.5)	8	(1.4)
Main 1.2 6.28 6.28 6.28 6.29 1000000 3 2.2 6.20 CBS total score 210-33 310-27 310-37 3	Gender, N (%)	274		(00.0)	915		(000)	Radiation		0	(0.0)	2	(0.4)
Clifs Year All geneine Xeen Cell transplantation Unit of the Xeen Cell transplantation Unit of the Xeen Cell transplantation Note	Male		172	(62.8)		628	(68.6)	Rituximab		3	(2.5)	29	(5.2)
Middle (Range) 2 [0 13] 3 [0 17] > 6 (%) 27 [16] 28 [16] 164 165 20 > 0 0.51 (23) (118) (42) (42) (42) (42) (42) (42) (42) (41) (41) (41) (42) <t< td=""><td>CIRS total score</td><td>165</td><td></td><td></td><td>491</td><td></td><td></td><td>Allogeneic stem cell transplantation</td><td></td><td>0</td><td>(0.0)</td><td>5</td><td>(0.9)</td></t<>	CIRS total score	165			491			Allogeneic stem cell transplantation		0	(0.0)	5	(0.9)
> 6 (b) 27 (16 4) 28 (16 4) <t< td=""><td>Median (Range)</td><td></td><td></td><td>2 (0-13)</td><td></td><td>3</td><td>(0-17)</td><td>All first administered subsequent treatments</td><td></td><td></td><td>DTV:</td><td></td><td></td></t<>	Median (Range)			2 (0-13)		3	(0-17)	All first administered subsequent treatments			DTV:		
All set deninstant weight (b)All (2)All (2)	> 6 (%)	101	27	(16.4)	404	81	(16.5)	after first Venetoclax/BTKi regimen	vene	etoclax	BIKI		
Construction Construction <th< td=""><td><pre>CIRS organ system neart, N (%) </pre></td><td>164</td><td>52</td><td>(32.3)</td><td>481</td><td>112</td><td>(24.5)</td><td>All last administered prior treatments</td><td>26</td><td></td><td>264</td><td></td><td></td></th<>	<pre>CIRS organ system neart, N (%) </pre>	164	52	(32.3)	481	112	(24.5)	All last administered prior treatments	26		264		
> 0 78 (47.3) 254 (52.1) 67 (22.4) 67 ECGG performance status, N (%) 160 475 475 1 0.0 1 0.0.1 1 0.0.4 = 0 80 (20.0) 204 (42.7) 27 41 15.2 1 0.0.0 1 0.0.4 1 <td>CIRS organ system blood pressure, N (%)</td> <td>165</td> <td></td> <td>(32.3)</td> <td>487</td> <td>110</td> <td>(24.5)</td> <td>Venetoclax-based</td> <td>6</td> <td>(23.1)</td> <td>68</td> <td>(25.8)</td> <td></td>	CIRS organ system blood pressure, N (%)	165		(32.3)	487	110	(24.5)	Venetoclax-based	6	(23.1)	68	(25.8)	
ECOC performance status, N(%) 160 476 Intercention (%) 0 <	>0		78	(47.3)	_	254	(52.2)	Venetoclax	6	(23.1)	6/	(25.4)	
= 0 80 50.0 20.4 42.9 - 1 6.6 42.9 (4.9) - 2 1 (6.9) 42 (8.8) - 3 1 (0.6) 3 (6.9) Biret stage, N (%) 137 42 (8.8) (6.9) 14 (0.4) - 4 1 (0.6) 13 (0.1) (0.1) (0.1) (0.1) A 29 (2.1) 9.2 (1.9) (1.1) (1.1) (1.1) (1.1) A 29 (2.1) (3.9) (3.9) (1.1) (1	ECOG performance status, N (%)	160			476			Anti-CD20+Venetoclax-based	2	(0.0) (7.7)	41	(15.2)	
-1 68 (42.5) 27 (47.7) -2 10 (6.9) 42 (8.1) (1.1)	= 0		80	(50.0)		204	(42.9)	Bendamustine/Obinutuzumab/Venetoclax	0	(0.0)	1	(0.4)	
= 2 11 [0-5] 32 (§ 8.5) = 3 1 (0.6) 3 0.6 Binet stage, N (%) 137 487 (1.8) Rituximab/Venetoclax 0 0 0.8 (3.0) A 2.9 (21.2) 92 (18.9) 138 10 (1.8) 6.6 (1.9) (1.6) (1	= 1		68	(42.5)		227	(47.7)	Cyclophosphamide/Doxorubicin/Prednisone/Rituximab/	0	(0.0)	1	(0.4)	
Delation 1 100 3 100 3 3 3 Delation 29 21.2 92 (18.9) 3 11.1 11.1 11.1 11.1 A 29 21.2 92 (18.9) 3 6 11.1 11	= 2		11	(6.9)		42	(8.8)	Vincristine/Venetoclax		(<i>/</i>	
A 29 (21.2) 92 (18.9) B 56 (40.9) 194 (38.8) 10 (38.5) 65 (24.6) Cytogenetic subgroup, N(%) 57 175 175 175 18.8) 2 (17.4) 11 (17.4) Deletion 17p 7 (12.3) 42 (24.0) 16 16.38.1 5 (19.2) 46 (17.4) Deletion 17p 7 (12.3) 42 (24.0) 16 18.8.1 5 (19.2) 46 (17.4) Deletion 17p 7 (12.3) 42 (24.0) 16 16.10/10/04inttzumab 1 (3.8) 2 (0.8) 66 Trisorny 12 4 (7.0) 19 (10.9) 16 16.10/10/04inttzumab/Tirabrutinib 0 (0.0) 1 (0.4) Idelatish/Dbinutzumab/Tirabrutinib/Obinutzumab/Venetoclax 1 (3.8) 1 (0.4) Mutatdo 32 (55.1) 10.8 (65.7) 10 Acalabrutinib/Obinutzumab/Venetoclax 1 (3.0) 0 (0.0) 1 <t< td=""><td>Binet stage, N (%)</td><td>137</td><td>T</td><td>(0.0)</td><td>487</td><td>3</td><td>(0.0)</td><td>Obinutuzumab/Venetoclax</td><td>0</td><td>(0.0)</td><td>8</td><td>(3.0)</td><td></td></t<>	Binet stage, N (%)	137	T	(0.0)	487	3	(0.0)	Obinutuzumab/Venetoclax	0	(0.0)	8	(3.0)	
B 56 (40.9) 194 (39.8) C 52 (30.0) 201 (41.3) Cytogenetic subgroup, N(%) 57 175 192.0 46 (17.4) Deletion 17p 7 (12.3) 22 (24.0) 1brutinib/Ofatunumab 1 (3.8) 2 (0.8) Deletion 11q 7 (12.3) 22 (12.4) 10 (13.8) 2 (0.8) No abnormalities 20 (35.1) 52 (27.7) Anti-CD20+BTK+Neentoclax-Seased 1 (3.8) 2 (0.8) Deletion 13q 20 (35.1) 52 (27.7) Acalabrutinib/Obinutuzumab/Tirabrutinib 0 (0.0) 1 (0.4) Deletion 13q 57 152 152 152 152 153 152 153 152 153 153 10.4	A		29	(21.2)		92	(18.9)	BTKi-based	2 10	(38.5)	51 65	(11.7)	
C 52 (38.0) 201 (41.3) Cycoenetic subgroup, N(%) 57 75 Deletion 17p (7) (12.3) 42 (24.0) Deletion 11q 7 (12.3) 42 (24.0) Trisomy 12 4 (7.0) 19 (10.9) (10.0) 1 (0.4) No abnormalities 20 (35.1) 52 (27.7) 16/4 (10.0) 1 (0.4) Ibrutinib/Ofaturuzmab/Tirabrutinib 0 (0.0) 1 (0.4) No abnormalities 20 (35.1) 52 (27.7) 14 (3.8) 0 (0.0) Ibrutinib/Ofaturuzmab/Tirabrutinib 0 (0.0) 1 (0.4) (0.4) Ibrutinib/Nituximab/Venetoclax 0 (0.0) 1 (0.4) Ibrutinib/Nituximab/Venetoclax 0 (0.0) <td>В</td> <td></td> <td>56</td> <td>(40.9)</td> <td></td> <td>194</td> <td>(39.8)</td> <td>Acalabrutinib</td> <td>5</td> <td>(19.2)</td> <td>19</td> <td>(7.2)</td> <td></td>	В		56	(40.9)		194	(39.8)	Acalabrutinib	5	(19.2)	19	(7.2)	
Cyclogenetic subgroup, N(%) 57 Inti-C020+BTKi-based 1 (3.8) 5 (1.9) Deletion 17p (12.3) 42 (24.0) Ibrutini/Obinutuzumab 1 (3.8) 2 (0.8) Deletion 14q (7.0) 19 (10.9) Ibrutinib/Obinutuzumab/Tirabrutinib 0 (0.0) 1 (0.4) No abnormalities 20 (35.1) 52 (27.7) Acalabrutinib/Obinutuzumab/Tirabrutinib 0 (0.0) 1 (0.4) IbHY mutation status, N(%) 74	C		52	(38.0)		201	(41.3)	Ibrutinib	5	(19.2)	46	(17.4)	
Deletion 1/p / 12.3 / 42 / 24.0 Deletion 1/p / 1 (3.8) 2 (0.8) Deletion 11q / 1 (1.2.3) 22 (12.6) Trisomy 12 / 4 (7.0) 19 (10.9) (14.3) 0 0.00 2 (0.8) No abnormalities 20 (35.1) 52 (27.7) 13 (12.9) 16/10/10/10/10/10/10/10/10/10/10/10/10/10/	Cytogenetic subgroup, N (%)	57			175	10		Anti-CD20+BTKi-based	1	(3.8)	5	(1.9)	
Detend rag (12.5) 2.2 (12.6) Trisomy 12 4 (7.0) 19 (10.9) <td< td=""><td>Deletion 1/p</td><td></td><td>7</td><td>(12.3)</td><td></td><td>42</td><td>(24.0)</td><td>Ibrutinib/Obinutuzumab</td><td>1</td><td>(3.8)</td><td>2</td><td>(0.8)</td><td></td></td<>	Deletion 1/p		7	(12.3)		42	(24.0)	Ibrutinib/Obinutuzumab	1	(3.8)	2	(0.8)	
No abbrailities 20 (35.1) 52 (27.7) Deletion 13q 19 (33.3) 40 (22.9) IGHV mutation status, N (%) 57 162 Day and the status, N (%) 57 162 Dry and the status, N (%) 57 162 Dry and the status, N (%) 74 182 TP53 mutation status, N (%) 74 182 Deletion and/or mutation 9 (12.2) 67 (36.8) TP53 status, N (%) 51 130 108 (6.7) Deletion and/or mutation 9 (12.6) 59 (45.4) Deletion and/or mutation 9 (17.6) 59 (45.4) Deletion and/or mutation 9 (17.6) 59 (45.4) Deletion and/or mutation 9 (17.6) 59 (45.4) Deverse N (%) 58 145 0 0 0.0 11 (4.2) Low 4 (6.9) 4 (2.8) 0 0 0.0 1 0.4 High 11 (3.3,4) 71	Trisomy 12		/ Д	(12.5)		19	(12.0)	Ibrutinib/Ofatumumab Idelalisib/Obiputuzumab/Tirabrutinib	0	(0.0)	2	(0.8)	
Deletion 13q 1 <t< td=""><td>No abnormalities</td><td></td><td>20</td><td>(35.1)</td><td></td><td>52</td><td>(27.7)</td><td>Anti-CD20+BTKi+Venetoclax-based</td><td>1</td><td>(3.8)</td><td>1</td><td>(0.4)</td><td></td></t<>	No abnormalities		20	(35.1)		52	(27.7)	Anti-CD20+BTKi+Venetoclax-based	1	(3.8)	1	(0.4)	
IGHV mutation status, N (%) 57 162 Unmutated 32 (5.6.1) 108 (6.7.7) 13 (4.9) TP53 mutation status, N (%) 74 182 (12.9) (14.9) (14.9) Mutated 9 (12.2) 67 (3.6.8) (14.9) (14.9) TP53 status, N (%) 51 130 (15.9) (16.9)	Deletion 13q		19	(33.3)		40	(22.9)	Acalabrutinib/Obinutuzumab/Venetoclax	1	(3.8)	0	(0.0)	
Unmutated 32 56.1 108 (66.7) TP53 mutation status, N (%) 74 182 Mutated 9 12.2 67 36.8 TP53 status, N (%) 51 130 (4.9) TP53 status, N (%) 51 130 (4.9) Deletion and/or mutation 51 130 (4.9) CLL-IPI score, N (%) 58 145 Other 2 (7.7) 34 (4.9) CLL-IPI score, N (%) 58 145 Other 2 (7.7) 26 (9.8) Intermediate 69.9 (4.5) (4.5) 0 (0.0) 1 (0.4) High (2.07) (2.07) (2.07) (2.07) (2.07) (2.07) (2.07) Very high (1.9) (3.1) (4.9) (4.9) (4.9) Mutated (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0)	IGHV mutation status, N (%)	57			162			Ibrutinib/Rituximab/Venetoclax	0	(0.0)	1	(0.4)	
TP53 mutation status, N (%) 74 182 Chemoimmunotherapy 2 (7.7) 34 (12.9) Mutated 9 (12.2) 67 (36.8) TP53 status, N (%) 51	Unmutated		32	(56.1)		108	(66.7)	Chemotherapy	2	(7.7)	13	(4.9)	
Mutated 9 12.2 67 (36.8) TP53 status, N (%) 51 130 Clipited 2 (7.7) 26 (9.8) Deletion and/or mutation 9 (17.6) 59 (45.4) Bortezomile 1 (3.8) 0 (0.0) 11 (4.2) Clupited 9 (17.6) 59 (45.4) Bortezomile 1 (3.8) 0 (0.0) Low 58 145	TP53 mutation status, N (%)	74	0	(12.2)	182	<u> </u>		Chemoimmunotherapy	2	(7.7)	34	(12.9)	
In solation, (v) Site Isolation Site Site <t< td=""><td>TP53 status N (%)</td><td>ς1</td><td>9</td><td>(12.2)</td><td>120</td><td>6/</td><td>(30.8)</td><td>Other</td><td>2</td><td>(0.0)</td><td>26</td><td>(4.2) (9.8)</td><td></td></t<>	TP53 status N (%)	ς1	9	(12.2)	120	6/	(30.8)	Other	2	(0.0)	26	(4.2) (9.8)	
CLL-IPI score, N (%) 58 145 Low 4 (6.9) 4 (2.8) Intermediate 0 (0.0) 9 (3.4) High 31 (53.4) 71 (49.0) Very high 11 (19.0) 46 (31.7)	Deletion and/or mutation	JI	Q	(17.6)	130	59	(45.4)	Bortezomib	1	(3.8)	0	(0.0)	
Low 4 (6.9) 4 (2.8) Intermediate 12 (20.7) 24 (16.6) High 31 (53.4) 71 (49.0) Very high 11 (19.0) 46 (31.7)	CLL-IPI score, N (%)	58	5	(=7:0)	145			Dexamethasone/Lenalidomide	0	(0.0)	1	(0.4)	
Intermediate 12 (20.7) 24 (16.6) High 31 (53.4) 71 (49.0) Very high 11 (19.0) 46 (31.7)	Low		4	(6.9)		4	(2.8)	Obinutuzumab	0	(0.0)	9	(3.4)	
High 31 (53.4) 71 (49.0) Very high 11 (19.0) 46 (31.7)	Intermediate		12	(20.7)		24	(16.6)	Ofatumumab	0	(0.0)	2	(0.8)	
Very high 1 (19.0) 46 (31.7)	High		31	(53.4)		71	(49.0)	Rituximab	0	(0.0)	7	(2.7)	
	Very high		11	(19.0)		46	(31.7)	Anogeneic stem cell transplantation	T	(3.8)	/	(2.7)	

Table 1) Patient characteristics

1212: Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry

Table 2) administered treatment by cohort



Figure 1) Survival from start of first Venetoclax containing regimen

Survival from first BTKi containing regimen					Rate (%) at month					
Survival	Ν	Events, N (%)	Median (months)	24	36	48	60			
OS	915	204 (22.3)	85.9	84.9	79.0	71.9	64.4			
TTNT	915	264 (28.9)	68.4	75.6	67.4	58.2	54.3			
EFS	915	395 (43.2)	23.2	48.6	32.3	20.2	12.7			



Figure 2) Survival from start of first BTKi containing regimen







Figure 3) Sankey plot of last previous treatments (before) first Venetoclax/BTKi regimen and first subsequent treatments (after) first Venetoclax/BTKi regimen

CONCLUSION

In our dataset of patients being treated within the GCLLSG registry between 2014 and 2023

targeted therapies with Venetoclax were administered as firstline treatment in 152 of 274 pts (55.5%)

while 352 of 915 pts (38.5%) were treated with a **BTKi** as firstline treatment.

If prior treatments were given, the majority of pts still received chemo(immuno)therapy.

EFS, TTNT and OS were comparable between the Venetoclax and BTKi-based treatment cohort.